Alfimeprase for Thrombolysis in Acute Peripheral Arterial Occlusion

ARCA Biopharma, Inc.100 enrolled

Overview

This trial is for patients with acute occlusion of one of the arteries supplying blood to the leg. The trial is designed to determine the safety and activity of a novel clot dissolving (thrombolytic) drug (alfimeprase).

Study Type

INTERVENTIONAL

Allocation

RANDOMIZED

Purpose

TREATMENT

Masking

NONE

Enrollment

100

Conditions

Arterial Occlusive Diseases Peripheral Vascular Diseases Thrombosis

Interventions

AlfimepraseDRUG

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

* Patients with acute peripheral arterial occlusion of the lower limb (onset of symptoms within 14 days) * Rutherford Class I or IIa (minimal sensory loss, no muscle weakness, audible venous flow) * Age 18 or above * Able to consent * Able to follow up

Locations (1)

Cleveland Clinic Foundation

Cleveland, Ohio, United States

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.